AI-Based Mobile Intervention on Medication Non-Adherence and Transition

Part of paid clinical trials in Orlando, Florida.

Sponsor
University of Central Florida
Study ID
NCT07445074
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
14 Years - 24 Years
Healthy Volunteers
Not accepted

Interventions

  • Medilepsy® Chatbot AI-Enhanced — OTHER
    Participants in the intervention group will use the AI-personalized version of the Medilepsy® app, which includes a Smart Chatbot that delivers interactive support based on user-entered data. The chatbot offers personalized prompts, relevant topic suggestions, and adaptive educational content to support epilepsy self-management.
  • Medilepsy® Chatbot Standard — OTHER
    Participants in the non-intervention group will use a standard version of the Medilepsy® app without AI functionality. This version includes static prompts and general educational links but does not provide personalized feedback or adaptive interaction.

Study Details

This study aims to examine whether the AI-personalized version of the Medilepsy® app is more effective than the non-AI (standard version without AI personalization) can improve key outcomes, such as medical adherence and transition readiness, among underserved adolescents and young adults with epilepsy, ages 14-24, in Florida, USA. Outcomes are organized into primary (effectiveness), secondary (usability), and exploratory (language experience) endpoints.

Key Dates

Start date
May 31, 2026
Status verified
May 2026
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
200 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE

Arms

  • Experimental: Medilepsy® Chatbot AI-Enhanced
    Participants in the intervention group will use the AI-personalized version of the Medilepsy® app.
  • Active Comparator: Medilepsy® Chatbot Standard
    Participants in the non-intervention group will use a standard version of the Medilepsy® app without AI functionality.

Primary Outcome Measure

Examine the effect of Medilepsy® with and without responsible AI design on medication adherence. [ Time Frame: 3-6 months ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Orlando Health Arnold Palmer HospitalOrlandoFlorida32806
Michelle Tall, PhD, RN, FAES
[email protected]
4077970100
Orlando Health Orlando Regional Medical CenterOrlandoFlorida32806
Michelle Tall, PhD, RN, FAES
[email protected]
4077970100
Michelle Tall, PhD, RN, FAES (PRINCIPAL_INVESTIGATOR)

Find similar trials in Orlando, FL

By condition
Epilepsy
By specialty
NeurologyBrain disorders
By research site
Orlando Health Arnold Palmer Hospital· Orlando, FLOrlando Health Orlando Regional Medical Center· Orlando, FL

Related Studies